These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 33741405)

  • 1. Oral efficacy of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model.
    Mitchell VA; Harley J; Casey SL; Vaughan AC; Winters BL; Vaughan CW
    Neuropharmacology; 2021 May; 189():108529. PubMed ID: 33741405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabis constituent synergy in a mouse neuropathic pain model.
    Casey SL; Atwal N; Vaughan CW
    Pain; 2017 Dec; 158(12):2452-2460. PubMed ID: 28885457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrathecal Actions of the Cannabis Constituents Δ(9)-Tetrahydrocannabinol and Cannabidiol in a Mouse Neuropathic Pain Model.
    Casey SL; Mitchell VA; Sokolaj EE; Winters BL; Vaughan CW
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single and combined effects of Δ
    King KM; Myers AM; Soroka-Monzo AJ; Tuma RF; Tallarida RJ; Walker EA; Ward SJ
    Br J Pharmacol; 2017 Sep; 174(17):2832-2841. PubMed ID: 28548225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
    Langford RM; Mares J; Novotna A; Vachova M; Novakova I; Notcutt W; Ratcliffe S
    J Neurol; 2013 Apr; 260(4):984-97. PubMed ID: 23180178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. THC and gabapentin interactions in a mouse neuropathic pain model.
    Atwal N; Casey SL; Mitchell VA; Vaughan CW
    Neuropharmacology; 2019 Jan; 144():115-121. PubMed ID: 30312630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
    Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabidiol Increases Psychotropic Effects and Plasma Concentrations of Δ
    Gorbenko AA; Heuberger JAAC; Klumpers LE; de Kam ML; Strugala PK; de Visser SJ; Groeneveld GJ
    Clin Pharmacol Ther; 2024 Nov; 116(5):1289-1303. PubMed ID: 39054656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabidiol modulation of antinociceptive tolerance to Δ
    Greene NZ; Wiley JL; Yu Z; Clowers BH; Craft RM
    Psychopharmacology (Berl); 2018 Nov; 235(11):3289-3302. PubMed ID: 30238130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cannabidiolic acid and ∆
    Rock EM; Limebeer CL; Parker LA
    Psychopharmacology (Berl); 2018 Nov; 235(11):3259-3271. PubMed ID: 30225659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination.
    Linher-Melville K; Zhu YF; Sidhu J; Parzei N; Shahid A; Seesankar G; Ma D; Wang Z; Zacal N; Sharma M; Parihar V; Zacharias R; Singh G
    PLoS One; 2020; 15(6):e0234176. PubMed ID: 32497151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Critical Review of the Role of the Cannabinoid Compounds Δ
    Jones É; Vlachou S
    Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain.
    Hoggart B; Ratcliffe S; Ehler E; Simpson KH; Hovorka J; Lejčko J; Taylor L; Lauder H; Serpell M
    J Neurol; 2015 Jan; 262(1):27-40. PubMed ID: 25270679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
    Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
    Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of cannabidiol (CBD) for the treatment of chronic pain.
    Urits I; Gress K; Charipova K; Habib K; Lee D; Lee C; Jung JW; Kassem H; Cornett E; Paladini A; Varrassi G; Kaye AD; Viswanath O
    Best Pract Res Clin Anaesthesiol; 2020 Sep; 34(3):463-477. PubMed ID: 33004159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment.
    Serpell M; Ratcliffe S; Hovorka J; Schofield M; Taylor L; Lauder H; Ehler E
    Eur J Pain; 2014 Aug; 18(7):999-1012. PubMed ID: 24420962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol.
    Vann RE; Gamage TF; Warner JA; Marshall EM; Taylor NL; Martin BR; Wiley JL
    Drug Alcohol Depend; 2008 Apr; 94(1-3):191-8. PubMed ID: 18206320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis.
    Jamontt JM; Molleman A; Pertwee RG; Parsons ME
    Br J Pharmacol; 2010 Jun; 160(3):712-23. PubMed ID: 20590574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
    J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.